The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes

Diabetes Care

Volumn 35, Issue 7, 2012, Pages 1552-1555

  Sosenko, Jay M ^a   Skyler, Jay S ^a   Mahon, Jeffrey ^b   Krischer, Jeffrey P ^c   Beam, Craig A ^c   Boulware, David C ^c   Greenbaum, Carla J ^d   Rafkin, Lisa E ^a   Cowie, Catherine ^e   Cuthbertson, David ^c   Palmer, Jerry P ^f  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE;

AGE; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES PREVENTION TRIAL TYPE 1 RISK SCORE; DIAGNOSTIC ACCURACY; DYSGLYCEMIA; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSTRUMENT VALIDATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; UPREGULATION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; PREDIABETIC STATE; RISK;

EID: 84862861874     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0011     Document Type: Article

References (20)

1. Diagnosis and classification of diabetes mellitus. DiabetesCare 2011;34(Suppl. 1):62-69
2. Gorsuch AN, Spencer KM, Lister J, et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981;2:1363-1365 (Pubitemid 12239439)
3. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-1339 (Pubitemid 14204704)
4. Baekkeskov S, Landin M, Kristensen JK, et al. Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. J Clin Invest 1987;79:926-934 (Pubitemid 17050921)
5. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
6. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
7. Sosenko JM, Palmer JP,Greenbaum CJ, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-649 (Pubitemid 44115367)
8. Sosenko JM, Palmer JP, Rafkin LE, et al.; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010;33:620-625
9. Sosenko JM, Krischer JP, Palmer JP, et al.; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:528-533
10. Sosenko JM, Skyler JS, Mahon J, et al.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Validation of theDiabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787
11. Orban T, Sosenko JM, Cuthbertson D, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:2269-2274
12. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698 (Pubitemid 34547482)
13. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152
14. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial. Lancet 2011; 378:412-419
15. Mrena S, Virtanen SM, Laippala P, et al. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006;29:662-667 (Pubitemid 44115370)
16. Sosenko JM, Palmer JP, Greenbaum CJ, et al.; Diabetes Prevention Trial-Type 1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2007; 30:38-42 (Pubitemid 46052498)
17. Barker JM, McFann K, Harrison LC, et al.; DPT-1 Study Group. Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J Pediatr 2007; 150:31-36, e6
18. Xu P, Wu Y, Zhu Y, et al.; Diabetes Prevention Trial-Type 1 (DPT-1) Study Group. Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes Care 2010;33:2508-2513
19. SteffesMW, Sibley S, JacksonM, ThomasW. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836 (Pubitemid 36929351)
20. The Diabetes Control and Complications Trial Research Group. Effect of in-tensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523